Purpose of Review
Rezum is a new minimally invasive treatment for benign prostate enlargement using thermal transurethral water vapour therapy. We review the evidence with advantages and disadvantages of this technique.
There are five studies reported including a randomised control trial looking at the outcomes of Rezum. The outcomes show an IPSS reduction by 45–60%, QoL improvement with a score reduction of 37–59%, the Qmax improvement by 44–72% and the PVR reduction by 20–38%.
Convective water vapour therapy using the Rezum system has been shown to have successful outcomes in the treatment of LUTS resulting from BPH. The reported complications are infrequent and often minor, and it seems to be relatively cost-effective.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Bin LK. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. Elsevier Ltd. 2017;4(3):148–51.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosear P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn [Internet. 2002;178:167–78.
Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2015;115:508–19.
Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology. 2001;58(01):25–32.
EAU Guidelines. Edn. Presented at the EAU Annual Congress Copenhagen. Arnhem: EAU Guidelines Office; 2018. https://uroweb.org/guidelines/compilations-of-all-guidelines. Accessed 3 March 2019.
Van AB, Barkin J, Elterman DS, Czerniak B, Dinney C, McConkey D, et al. Hyperplasia : a review. Curr Opin Oncol. 2014;23:863–910.
Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;
Jones P, Rajkumar GN, Rai BP, Aboumarzouk OM, Cleaveland P, Srirangam SJ, et al. Medium-term outcomes of Urolift (minimum 12 months follow-up): evidence from a systematic review. Urology. Elsevier Inc. 2016;97:20–4.
Jones P, Rai BP, Nair R, Somani BK. Current status of prostate artery embolization for lower urinary tract symptoms: review of world literature. Urology. 2015:676–81.
•• McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology [internet]. Elsevier Inc.; 2019;126:171–179. This paper outlines data collected in the only double blinded randomised control trial using Rezum. As of 2019 data are avialble for four years post implementation of the therapy. The study also features the largest number of participants.
National Institute for Health and Care Excellence (NICE). Medtech innovation briefing (MIB158). Rezum for treating benign prostatic hyperplasia. London: NICE; 2018.
• Mynderse LA, Hanson D, Robb RA, Pacik D, Vit V, Varga G et al. Rezu¯m system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. Urology. Elsevier Inc.; 2015;86(1):122–7. This paper provided objective data on the efficacy of Rezum and its viability for bringing about reduction in prostatic volume.
Somani BK, Westwood J, Rai BP, Jones P, Geraghty R. Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia. Ther Adv Urol. 2018;10:327–33.
Gittelman MC, Gange SN, Patel K, Roehrborn CG, Beahrs JR, Levin RM, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol Elsevier Ltd. 2016;197(6):1507–16.
Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. Elsevier Inc. 2015;86(5):1042–7.
Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–16.
Shore ND, McVary KT, Roehrborn CG, Kaminetsky J, Dixon CM, Cantrill CH, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol Elsevier Ltd. 2015;195(5):1529–38.
Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197:1507–16.
Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159–68.
Mollengarden D, Goldberg K, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis Springer US. 2018;21:379–85.
Gupta N, Rogers T, Holland B, Helo S, Dynda D, McVary KT. Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: cohort data from the MTOPS trial. J Urol [Internet] Elsevier Ltd. 2018;200(2):405–13.
McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med [Internet] Elsevier. 2016;13(6):924–33.
McVary KT, Rogers T, Mahon J, Gupta NK. Is sexual function better preserved after water vapor thermal therapy or medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia? J Sex Med. 2018;15:1728–38.
• Ulchaker J, Martinson M. Analyzing the Cost-Effectiveness of Six Therapies for Treating Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia. J Urol. 2018;199:29–43 In-depth analysis of the costs associated with new minimally invasive prosate therapies. Highlights potential for implementation within various health services.
Otto B, et al. Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Advances Urol. 2014;2014:627290. https://doi.org/10.1155/2014/627290.
Abedi AR, Fallah-Karkan M, Allameh F, Ranjbar A, Shadmehr A. Incidental prostate cancer: a 10-year review of a tertiary center, Tehran, Iran. Res Rep Urol. 2018;10:1–6.
McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology Elsevier Inc. 2018;111:1–9.
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Conflict of Interest
Zachary Green and Jennifer Westwood each declare no potential conflicts of interest.
Bhaskar K. Somani is a section editor for Current Urology Reports.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Benign Prostatic Hyperplasia
About this article
Cite this article
Green, Z., Westwood, J. & Somani, B.K. What’s New in Rezum: a Transurethral Water Vapour Therapy for BPH. Curr Urol Rep 20, 39 (2019). https://doi.org/10.1007/s11934-019-0903-7
- Water vapour therapy
- Minimally invasive therapy